NASDAQ:MGRX
Mangoceuticals, Inc.
Mangoceuticals, Inc.'s revenue fell 26.0% in fiscal 2025 to $456,021 while operating margin fell to −3954.3%. The diluted share count rose 408.9%.Summary generated from Mangoceuticals, Inc.'s SEC filings. Latest annual report filed Apr 1, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$456,021
Revenue growth−26.0%
Revenue, 5-yr CAGRn/a
Gross margin54.9%
Operating margin−3954.3%
Net margin−4526.8%
ROICn/a
Return on equity−141.6%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+408.9%
Financials
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 0 | 1 | 1 | 0 |
| Operating income | −2 | −9 | −8 | −18 |
| Net income | −2 | −9 | −9 | −21 |
| Free cash flow | −1 | −7 | n/a | n/a |
Recent filings
- 8-KEntry into a material agreement
Oct 9, 2026 - 4Insider transaction report
Oct 6, 2026 - 4Insider transaction report
Oct 6, 2026 - 8-KEntry into a material agreement
Oct 1, 2026 - 8-KTermination of a material agreement
Aug 21, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026 - 8-KOther events
Aug 4, 2026 - 8-KEntry into a material agreement
Jul 30, 2026